54244-58-5

Upstream product

• 15149-72-1 N-(N-benzyloxycarbonyl-L-valyl)-L-tyrosine methyl ester 
• 25518-33-6 methyl (tert-butoxycarbonyl)-L-valyl-L-tyrosinate 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 13734-41-3 t-Boc-L-valine 
• 10512-93-3 Z-Val-ONp 
• 1080-06-4 L-Tyr-OMe 
• 3417-91-2 L-tyrosine methyl ester HCl 
• 862-26-0 N^α-benzyloxycarbonylvalyltyrosine 
• 47522-06-5 (L)-Trt-Val-OH 

Downstream Products

• 108722-10-7 1-benzyl-N^α-benzyloxycarbonyl-L-histidyl=>L-valyl=>L-tyrosine-methyl ester 
• 398526-17-5 (2S)-[(2S)-((2S)-tert-butoxycarbonylamino-6-hydroxyhexanoylamino)-3-methyl-butyrylamino]-3-(4-hydroxyphenyl)propionic acid methyl ester 
• 85471-58-5 H-L-Arg-L-Lys-L-Asp-L-Val-L-Tyr-OH*3HOAc 
• 75958-14-4 Aspartyl-valyl-tyrosine 
• 127290-80-6 C₆₂H₇₃N₉O₁₇ 
• 398526-27-7 ((7S,10S,13S)-13-{(R)-2-[(4-Acetylamino-benzenesulfonyl)-(3-methyl-butyl)-amino]-1-hydroxy-ethyl}-10-isopropyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.2.2]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-trien-7-yl)-carbamic acid tert-butyl ester 
• 398526-26-6 4-Amino-N-[(R)-2-((7S,10S,13S)-7-amino-10-isopropyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.2.2]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-trien-13-yl)-2-hydroxy-ethyl]-N-(3-methyl-butyl)-benzenesulfonamide 
• 479207-66-4 3,7-Dimethyl-octanoic acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 
• 479207-65-3 Octanoic acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 
• 479207-64-2 (S)-2-[(S)-2-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-3-(4-phenylacetoxy-phenyl)-propionic acid methyl ester 
• 479207-63-1 Hexanoic acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 
• 479207-67-5 Benzoic acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 
• 479207-62-0 3-Methyl-butyric acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 
• 479207-61-9 3-Methyl-but-2-enoic acid 4-{(S)-2-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-methyl-butyrylamino]-2-methoxycarbonyl-ethyl}-phenyl ester 

Relevant academic research and scientific papers

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Structures, sensory activity, and dose/response functions of 2,5-diketopiperazines in roasted cocoa nibs (Theobroma cacao)

The taste compounds inducing the blood-like, metallic bitter taste sensation reported recently for a dichloromethane extract prepared from roasted cocoa nibs were identified as a series of 25 diketopiperazines by means of HPLC degustation, LC-MS/MS, and i

β-strand mimicking macrocyclic amino acids: Templates for protease inhibitors with antiviral activity

New amino acids are reported in which component macrocycles are constrained to mimic tripeptides locked in a β-strand conformation. The novel amino acids involve macrocycles functionalized with both an N- and a C-terminus enabling addition of appendages a

Development of tripeptidyl farnesyltransferase inhibitors.

The first example of tripeptide inhibitors of farnesyltransferase with sub-micromolar inhibition activity was developed based on the fact that CVFM is not a substrate for farnesyltransferase.